The effect of lipid lowering by Acipimox on cardiac and skeletal muscle mitochondrial function.

Completed

• Conditions: sugar and heartfailure; 10019280; 10012653

• Registration Number: NL-OMON35239
• Lead Sponsor: Center for Translational Molecular Medicine (CTMM)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

- male
- BMI>30kg/m2
- non-insulin dependant type 2 DM or controls
- no cardiovascular or DM related diseases
- Use of only metformin or SU-derivates

Exclusion Criteria

- no contra-indications for MRS
- No contra-indications Acipimox
- no weight loss/gain last 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study parameters are the changes in mitochondrial function, lipid<br /><br>accumulation and cardiac function after Acipimox treatment, compared to the<br /><br>placebo treatment group. As secondary endpoints in changes insulin<br /><br>sensitivity, oxidative stress markers and the relationship with the tissue<br /><br>parameter lipid accumulation are considered.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>As secondary endpoints in changes insulin sensitivity, oxidative stress markers<br /><br>and the relationship with the tissue parameter lipid accumulation are<br /><br>considered.</p><br>